• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

    15.72 -0.18 (-1.13%)
    Streaming Delayed Price Updated: 11:35 AM EST, Jan 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Summit Therapeutics Inc. - Common Stock

    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 13
    ...
    17 18 Next >
    News headline image
    (SMMT) - Analyzing Summit Therapeutics's Short Interest ↗
     
    Via Benzinga
    News headline image
    2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts ↗
    The investment bank analysts who follow these stocks think they can soar even further, with some caveats. 
    Via The Motley Fool
    News headline image
    Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio? ↗
    Eleven large-cap stocks were worst performers last week. Decline in Stars performance and sales, regulations and supply issues caused the drop. 
    Via Benzinga
    News headline image
    Is Summit Therapeutics a Millionaire Maker? ↗
    This company's promising cancer drug could challenge Merck's $25 billion crown jewel. 
    Via The Motley Fool
    News headline image
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Summit Therapeutics Inc.
    Via Business Wire
    News headline image
    Here's How Much $100 Invested In Summit Therapeutics 5 Years Ago Would Be Worth Today ↗
     
    Via Benzinga
    News headline image
    Could Summit Therapeutics Become the Next Merck? ↗
    Recent developments are forcing comparisons between these two drugmakers. 
    Via The Motley Fool
    News headline image
    Why Phoenix Motor Shares Are Trading Higher By 150%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
    From Summit Therapeutics Inc.
    Via Business Wire
    News headline image
    Where Will Summit Therapeutics Be in 3 Years? ↗
    There's a lot riding on how its collaborator's studies end up performing. 
    Via The Motley Fool
    News headline image
    EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank? ↗
    A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar. 
    Via Benzinga
    News headline image
    Has Summit Therapeutics Stock Already Peaked? ↗
    Summit Therapeutics stock is up a remarkable 700% this year. 
    Via The Motley Fool
    News headline image
    Is Summit Therapeutics Stock a Buy? ↗
    Its alliance with a successful foreign biotech could be decisive for the stock. 
    Via The Motley Fool
    News headline image
    Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio? ↗
    10 worst performing large-cap stocks last week: SMMT, MMYT, MEDP, REGN, GPN, AFRM, SMCI, FTI, FCNCA, NOW. Are they in your portfolio? 
    Via Benzinga
    News headline image
    2 High-Potential Growth Stocks You Shouldn't Overlook ↗
    These two growth stocks have plenty of room to run. 
    Via The Motley Fool
    News headline image
    Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics ↗
    One of them is performing much better than the other this year. 
    Via The Motley Fool
    News headline image
    2 Stocks Up Over 700% in 2024 That Could Soar Even Further ↗
    These relatively small companies are developing new cancer therapies that could generate billions in annual sales. 
    Via The Motley Fool
    News headline image
    Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? ↗
    10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% 
    Via Benzinga
    News headline image
    This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy? ↗
    How long will the momentum last? 
    Via The Motley Fool
    Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
    Via AB Newswire
    News headline image
    Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
    Summit Therapeutics' rise could signal emerging opportunities in precision oncology such Nuvectis Pharma (NASDAQ: NVCT), Silexion (NASDAQ:SLXN), and Scorpion leading the charge. 
    Via News Direct
    News headline image
    Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year? ↗
    The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a late-stage clinical study. 
    Via The Motley Fool
    News headline image
    This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous. ↗
    There's a lot of hope for ivonescimab, but are investors being a bit too bullish? 
    Via The Motley Fool
    News headline image
    How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery ↗
    BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days. 
    Via Investor's Business Daily
    News headline image
    Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study ↗
    Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival... 
    Via Benzinga
    News headline image
    Here's Why Everyone's Talking About Summit Therapeutics ↗
    Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock. 
    Via The Motley Fool
    News headline image
    Alphabet To $200? Here Are 10 Top Analyst Forecasts For Monday ↗
     
    Via Benzinga
    News headline image
    Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
    From Summit Therapeutics Inc.
    Via Business Wire
    News headline image
    Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio? ↗
    These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings. 
    Via Benzinga
    News headline image
    Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? ↗
    A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy. 
    Via The Motley Fool
    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 13
    ...
    17 18 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.